Submitted by Anonymous (not verified) on 29 August 2023 - 12:00
Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, Breast Neoplasms, Date of authorisation: 04/03/2013, Revision: 22, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, Breast Neoplasms, Date of authorisation: 04/03/2013, Revision: 22, Status: Authorised